Added Value of a Neuroendocrine Test Battery in the Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment

Summary

The primary objective of the study is to determine the predictive value of the neuroendocrine tests TRH-∆∆TSH (thyreoliberin - thyreostimulin) and DST (dexamethasone suppression test) in the subsequent response to rTMS-TBS (repetitive transcranial magnetic stimulation-theta burst stimulation) treatment, defined as at least a 50% decrease in depression score after 20 sessions of rTMS-TBS.

Eligibility

Inclusion Criteria:

1. Patient with a characterized depressive episode defined according to DSM-5 (diagnostic and statistical manual of mental disorders) criteria;
2. Patient between the ages of 18 and 65 years;
3. Inpatient with an inadequate response to two prior well-conducted antidepressant treatments (Hamilton 17-item scale \[HAMD-17\] score at inclusion≥ 18) ;
4. Patient with written informed consent to participate in the study;
5. Patient enrolled in or receiving social security benefits.

Exclusion Criteria:

1. Patient with endocrinopathy ;
2. Patient with a contraindication to neuroendocrine testing (hypersensitivity to the active substance or to one of the excipients);
3. Patient with a contraindication to rTMS:

   * cochlear implant,
   * cardiac pacemaker,
   * metal clips, stents or other electronic implants within one meter of the stimulation coil,
   * intracranial hypertension,
   * poorly balanced comitiality,
   * in the case of well-balanced comitiality, a neurological consultation with electroencephalogram (EEG) is planned before including the patient;
4. Patient previously treated with monoamine oxidase inhibitor (MAOI) antidepressant or lithium salts (within 6 months prior to inclusion);
5. Pregnant or lactating patient;
6. Patient under court protection or deprived of liberty;
7. Patient under guardianship/guardianship.

Conditions2

Browse More Trials